Patent ID: 8618172

Claim:
A solid oral dosage form comprising (i) 28-44% aliskiren, or a pharmaceutically acceptable salt thereof, by weight based on the total weight of the oral dosage form; (ii) 1.4-5.5% hydrochlorothiazide by weight based on the total weight of the oral dosage form; and (iii) 5-25% carbohydrate hydrophilic filler by weight based on the total weight of the oral dosage form, wherein the carbohydrate hydrophilic filler is a mixture of wheat starch and lactose; (iv) 22-33% microcrystalline cellulose, by weight based on the total weight of the oral dosage form; (v) 9-13% crosslinked polyvinylpyrrolidone, by weight based on the total weight of the oral dosage form; (vi) 0.6-1.8% colloidal silicon dioxide, by weight based on the total weight of the oral dosage form; (vii) 0.4-1.8% talc, by weight based on the total weight of the oral dosage form; (viii) 1-1.5% magnesium stearate, by weight based on the total weight of the oral dosage form; and (ix) 2.1-3.2% polyvinylpyrrolidone, by weight based on the total weight of the oral dosage form.